JP2014509655A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014509655A5 JP2014509655A5 JP2014502835A JP2014502835A JP2014509655A5 JP 2014509655 A5 JP2014509655 A5 JP 2014509655A5 JP 2014502835 A JP2014502835 A JP 2014502835A JP 2014502835 A JP2014502835 A JP 2014502835A JP 2014509655 A5 JP2014509655 A5 JP 2014509655A5
- Authority
- JP
- Japan
- Prior art keywords
- weight
- pharmaceutical composition
- pharmaceutically acceptable
- acceptable salt
- diazepam
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 150000003839 salts Chemical class 0.000 claims 22
- 229960003529 diazepam Drugs 0.000 claims 20
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims 20
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims 20
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 18
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims 18
- UQDUPQYQJKYHQI-UHFFFAOYSA-N methyl laurate Chemical compound CCCCCCCCCCCC(=O)OC UQDUPQYQJKYHQI-UHFFFAOYSA-N 0.000 claims 16
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 claims 12
- 229940035044 sorbitan monolaurate Drugs 0.000 claims 12
- 229920002675 Polyoxyl Polymers 0.000 claims 11
- 125000005456 glyceride group Chemical group 0.000 claims 11
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims 9
- GHHURQMJLARIDK-UHFFFAOYSA-N 2-hydroxypropyl octanoate Chemical compound CCCCCCCC(=O)OCC(C)O GHHURQMJLARIDK-UHFFFAOYSA-N 0.000 claims 8
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 2
- 229940049706 benzodiazepine Drugs 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- 150000001336 alkenes Chemical class 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- -1 fatty acid esters Chemical class 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims 1
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161469940P | 2011-03-31 | 2011-03-31 | |
| US61/469,940 | 2011-03-31 | ||
| PCT/US2012/031453 WO2012135619A2 (en) | 2011-03-31 | 2012-03-30 | Intranasal benzodiazepine pharmaceutical compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014509655A JP2014509655A (ja) | 2014-04-21 |
| JP2014509655A5 true JP2014509655A5 (enExample) | 2015-05-14 |
Family
ID=46928023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014502835A Pending JP2014509655A (ja) | 2011-03-31 | 2012-03-30 | 鼻腔内ベンゾジアゼピン薬剤学的組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20120252793A1 (enExample) |
| EP (1) | EP2691100A4 (enExample) |
| JP (1) | JP2014509655A (enExample) |
| KR (1) | KR20140029426A (enExample) |
| CN (1) | CN103619338B (enExample) |
| AR (1) | AR085927A1 (enExample) |
| AU (1) | AU2012236334B2 (enExample) |
| BR (1) | BR112013024968A2 (enExample) |
| CA (1) | CA2831308A1 (enExample) |
| MX (1) | MX357800B (enExample) |
| PH (2) | PH12013501915A1 (enExample) |
| RU (2) | RU2013148120A (enExample) |
| SG (2) | SG193958A1 (enExample) |
| TW (1) | TWI601532B (enExample) |
| WO (1) | WO2012135619A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101517415B1 (ko) | 2008-05-14 | 2015-05-07 | 에스케이바이오팜 주식회사 | 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물 |
| JP5929800B2 (ja) * | 2012-04-03 | 2016-06-08 | コニカミノルタ株式会社 | 定着液および画像形成方法 |
| WO2018222922A1 (en) * | 2017-06-02 | 2018-12-06 | Xeris Pharmaceuticals, Inc. | Precipitation resistant small molecule drug formulations |
| US20210161870A1 (en) | 2017-06-07 | 2021-06-03 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
| US12011437B1 (en) | 2017-06-07 | 2024-06-18 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
| US9895359B1 (en) | 2017-06-07 | 2018-02-20 | Arcutis, Inc. | Inhibition of crystal growth of roflumilast |
| US11129818B2 (en) | 2017-06-07 | 2021-09-28 | Arcutis Biotherapeutics, Inc. | Topical roflumilast formulation having improved delivery and plasma half life |
| US12042487B2 (en) | 2018-11-16 | 2024-07-23 | Arcutis Biotherapeutics, Inc. | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
| US20200155524A1 (en) | 2018-11-16 | 2020-05-21 | Arcutis, Inc. | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
| US11534493B2 (en) * | 2017-09-22 | 2022-12-27 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents |
| AU2019205329B2 (en) | 2018-01-05 | 2023-04-20 | Impel Pharmaceuticals Inc. | Intranasal delivery of olanzapine by precision olfactory device |
| WO2019182745A1 (en) * | 2018-03-19 | 2019-09-26 | Bryn Pharma, LLC | Epinephrine spray formulations |
| CN112384199A (zh) | 2018-06-04 | 2021-02-19 | 阿尔库缇斯股份有限公司 | 改善罗氟司特皮肤渗透滞后时间的方法和制剂 |
| CN111529489A (zh) * | 2020-04-17 | 2020-08-14 | 山东省药学科学院 | 一种含有地西泮的鼻腔喷雾剂 |
| AU2021393513A1 (en) | 2020-12-04 | 2023-07-06 | Arcutis Biotherapeutics, Inc. | Topical roflumilast formulation having antifungal properties |
| US12453721B2 (en) | 2021-12-28 | 2025-10-28 | Arcutis Biotherapeutics, Inc. | Topical roflumilast aerosol foams |
| JP2025530005A (ja) | 2022-09-15 | 2025-09-09 | アーキュティス・バイオセラピューティクス・インコーポレーテッド | ロフルミラスト及び大量のロフルミラストを溶解可能な溶媒の医薬組成物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE229817T1 (de) * | 1996-10-24 | 2003-01-15 | Alza Corp | Penetrationsfördernde substanzen für die transdermale verabreichung von wirkstoffen, vorrichtungen und verfahren zur herstellung |
| EP1196156B1 (en) * | 1999-07-26 | 2008-04-30 | SK Holdings Co., Ltd. | Transnasal anticonvulsive compositions |
| DK1539285T4 (da) * | 2002-09-03 | 2012-01-02 | Pharmacure Health Care Ab | Næsesprayer |
| TW200824693A (en) * | 2006-08-28 | 2008-06-16 | Jazz Pharmaceuticals Inc | Pharmaceutical compositions of clonazepam and methods of use thereof |
| US7745430B2 (en) * | 2006-11-15 | 2010-06-29 | Sk Holdings Co., Ltd. | Transnasal anticonvulsive pharmaceutical composition |
| US8946208B2 (en) * | 2007-08-31 | 2015-02-03 | Archimedes Development Limited | Non-aqueous pharmaceutical composition |
| KR101517415B1 (ko) * | 2008-05-14 | 2015-05-07 | 에스케이바이오팜 주식회사 | 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물 |
| US8242141B2 (en) * | 2009-09-16 | 2012-08-14 | Allergan, Inc. | Compositions and methods for treating seizure disorders |
-
2012
- 2012-03-30 RU RU2013148120/15A patent/RU2013148120A/ru not_active Application Discontinuation
- 2012-03-30 MX MX2013011336A patent/MX357800B/es active IP Right Grant
- 2012-03-30 US US13/435,837 patent/US20120252793A1/en not_active Abandoned
- 2012-03-30 SG SG2013072319A patent/SG193958A1/en unknown
- 2012-03-30 WO PCT/US2012/031453 patent/WO2012135619A2/en not_active Ceased
- 2012-03-30 EP EP12763553.0A patent/EP2691100A4/en not_active Ceased
- 2012-03-30 TW TW101111309A patent/TWI601532B/zh not_active IP Right Cessation
- 2012-03-30 CN CN201280017015.8A patent/CN103619338B/zh active Active
- 2012-03-30 KR KR1020137028968A patent/KR20140029426A/ko not_active Ceased
- 2012-03-30 JP JP2014502835A patent/JP2014509655A/ja active Pending
- 2012-03-30 BR BR112013024968A patent/BR112013024968A2/pt not_active Application Discontinuation
- 2012-03-30 SG SG10201602176RA patent/SG10201602176RA/en unknown
- 2012-03-30 AU AU2012236334A patent/AU2012236334B2/en not_active Ceased
- 2012-03-30 RU RU2018135967A patent/RU2018135967A/ru not_active Application Discontinuation
- 2012-03-30 PH PH1/2013/501915A patent/PH12013501915A1/en unknown
- 2012-03-30 CA CA2831308A patent/CA2831308A1/en not_active Abandoned
- 2012-04-03 AR ARP120101144A patent/AR085927A1/es unknown
-
2014
- 2014-01-14 US US14/154,575 patent/US20140128381A1/en not_active Abandoned
-
2016
- 2016-06-30 US US15/198,884 patent/US20170151258A1/en not_active Abandoned
-
2017
- 2017-09-15 PH PH12017501688A patent/PH12017501688A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014509655A5 (enExample) | ||
| RU2018135967A (ru) | Интраназальные фармацевтические композиции на основе бензодиазепина | |
| WO2009139589A3 (en) | Transnasal anticonvulsive pharmaceutical composition comprising poorly soluble anticonvulsant | |
| EP2827868A4 (en) | PHARMACEUTICAL COMPOSITIONS WITH FATTY ACID ESTERS | |
| EP2598148A4 (en) | PHARMACEUTICAL COMPOSITIONS WITH PEMETREXED WITH EXTENDED STORAGE STABILITY | |
| RU2015136849A (ru) | Композиции, содержащие 15-он эпк, и способы их применения | |
| JP2012524771A5 (enExample) | ||
| DOP2012000264A (es) | Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan | |
| DK4338805T3 (da) | Eicosapentaensyreethylester til brug for at reducere risikoen for ikke-dødeligt myokardieinfarkt hos en patient i statinbehandling | |
| JP2014218522A5 (enExample) | ||
| EP2822923A4 (en) | PREPARATION OF ALPHA, BETA-UNSATURATED CARBOXYLIC ACIDS AND THEIR ESTERS | |
| EP2800563A4 (en) | DPA-ENRICHED COMPOSITIONS OF MULTIPLE-UNSATURATED OMEGA-3 FATTY ACIDS IN A FREE ACID FORM | |
| JP2011140525A5 (enExample) | ||
| PE20161373A1 (es) | Composiciones de liberacion retardada de linaclotida | |
| EA201201050A1 (ru) | Пиразолы в качестве антагонистов crth2 | |
| EP2747832A4 (en) | AGGREGATE FORMULATIONS FOR DELAYED RELEASE | |
| EP2643002A4 (en) | PHARMACEUTICAL FORMULATIONS WITH CORTICOSTEROIDS FOR TOPICAL ADMINISTRATION | |
| EP2623100A4 (en) | Preparation for improving solubility of poorly soluble drug | |
| FR3015260B1 (fr) | Composition anhydre anti-transpirante sous forme d'aerosol comprenant un actif anti-transpirant et un polymere ethylenique filmogene non hydrosoluble et sequence | |
| FR2981572B1 (fr) | Compositions pharmaceutiques d'acide ursodesoxycholique | |
| EP2827867A4 (en) | PHARMACEUTICAL COMPOSITIONS WITH GLYCERINESTERS | |
| EP2906244A4 (en) | SILK RESERVOIRS FOR THE DELAYED RELEASE OF ANTI-CANCER | |
| EA201500513A1 (ru) | Продукт сомикронизации, включающий ацетат улипристала | |
| JP2013525485A5 (enExample) | ||
| PH12017500269A1 (en) | Composite formulation for oral administration comprising omega-3 fatty acid esters and statins |